Sarilumab:A New Arsenal for Rheumatoid Arthritis
Loading...
Date
2017-02
Journal Title
Journal ISSN
Volume Title
Publisher
Dr. J.S. Sodhi Memorial Educational Society
Abstract
Rheumatoid arthritis is a debilitating disease that has significant impact on quality of life. Biological and non biological DMARDs improved the outcome in RA patients. New agents are still required in inadequate responders or intolerant patients. FDA has recently approved a new drug Sarilumab, a monoclonal antibody for the treatment of moderate to severe form of RA which acts by binding to Interleukin receptor 6 and interrupts the resultant cytokine-mediated inflammatory signaling.
Description
Keywords
L-6, Monoclonal Antibody, Sarilumab, Cytokine, Pharmacy and Pharmacology